ArticleFrontiers in oncology2021
Role of HMGB1 in Cisplatin-Persistent Lung Adenocarcinoma Cell Lines.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- HMGB1: A Central Node in Cancer Therapy Resistance.International journal of molecular sciences · 2025Review
- Recent Advances on Pt-Based Compounds for Theranostic Applications.Molecules (Basel, Switzerland) · 2024Review
- Multiple functions of HMGB1 in cancer.Frontiers in oncology · 2024Review
- Article
- Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects.Medical oncology (Northwood, London, England) · 2023Review
- Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer.Molecular therapy oncolytics · 2023Article
- Transcriptional signature of early cisplatin drug-tolerant persister cells in lung adenocarcinoma.Frontiers in oncology · 2023Article
- Grape-Seed-Derived Procyanidin Attenuates Chemotherapy-Induced Cognitive Impairment by Suppressing MMP-9 Activity and Related Blood-Brain-Barrier Damage.Brain sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significant advances have been made recently in the development of targeted therapy for lung adenocarcinoma. However, platinum-based chemotherapy remains as the cornerstone in the treatment of this neoplasm. This is the treatment option for adenocarcinomas without
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.